Twist Bioscience (NASDAQ:TWST) Given New $56.00 Price Target at Evercore ISI

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its target price upped by Evercore ISI from $52.00 to $56.00 in a report released on Tuesday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Evercore ISI's target price would indicate a potential upside of 29.03% from the stock's current price.

TWST has been the topic of several other reports. Robert W. Baird boosted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research note on Monday, August 5th. TD Cowen upped their price objective on Twist Bioscience from $55.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, June 13th. The Goldman Sachs Group upped their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, July 9th. Finally, Barclays lowered their price objective on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $51.63.

Twist Bioscience Trading Down 3.9 %

TWST traded down $1.78 on Tuesday, hitting $43.40. 801,538 shares of the stock traded hands, compared to its average volume of 992,638. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $60.90. The firm has a market capitalization of $2.53 billion, a PE ratio of -12.92 and a beta of 1.76. The business has a fifty day moving average price of $46.09 and a two-hundred day moving average price of $43.50.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the prior year, the firm earned ($1.01) earnings per share. The company's revenue was up 27.7% on a year-over-year basis. On average, equities research analysts forecast that Twist Bioscience will post -3.13 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,137 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the sale, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the company's stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total transaction of $124,960.34. Following the transaction, the chief operating officer now owns 171,212 shares of the company's stock, valued at approximately $9,694,023.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Paula Green sold 1,137 shares of the company's stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the transaction, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. The disclosure for this sale can be found here. Insiders have sold a total of 15,348 shares of company stock worth $673,091 in the last three months. Insiders own 3.92% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in shares of Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company's stock valued at $5,895,000 after purchasing an additional 44,349 shares during the period. UBS Group AG raised its stake in Twist Bioscience by 106.4% during the 4th quarter. UBS Group AG now owns 213,467 shares of the company's stock worth $7,868,000 after buying an additional 110,036 shares during the period. SageView Advisory Group LLC acquired a new stake in Twist Bioscience during the 1st quarter worth $1,144,000. Susquehanna Fundamental Investments LLC acquired a new stake in Twist Bioscience during the 1st quarter worth $300,000. Finally, Sei Investments Co. raised its stake in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company's stock worth $7,670,000 after buying an additional 55,124 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.